Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

VYNE Therapeutics (VYNE) Receivables - Other (2020 - 2021)

VYNE Therapeutics' Receivables - Other history spans 2 years, with the latest figure at $5.5 million for Q4 2021.

  • For Q4 2021, Receivables - Other fell 5.17% year-over-year to $5.5 million; the TTM value through Dec 2021 reached $5.5 million, down 5.17%, while the annual FY2021 figure was $5.5 million, 5.17% down from the prior year.
  • Receivables - Other reached $5.5 million in Q4 2021 per VYNE's latest filing, down from $7.3 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $8.1 million in Q1 2021 to a low of $4.0 million in Q2 2020.